Get instant alerts when information breaks on your shares. Claim your 1-7 days absolutely free trial to StreetInsider High quality below.
BRYAN, Texas, Dec. 21, 2021 (Globe NEWSWIRE) — iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), a developer of next-era biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Production System®, delivers the adhering to backlink to hear practically to the 2021 Yearly Shareholders meeting: www.virtualshareholdermeeting.com/IBIO2021. The meeting will be held at 9:00 AM EST on December 22, 2021.
iBio had partly adjourned the 2021 Yearly Stockholder meeting similar to Proposal 4 (Reverse Inventory Break up) and Proposal 5 (Transform in Approved Shares) to make it possible for a lot more shareholders to vote. Earlier 64% and 67% of shareholders had voted in favor of these proposals, but extra shareholder votes are necessary to ratify the proposals.
If you have already voted your shares “FOR” Proposals 4 and 5, you do not want to vote all over again, and we thank you for your help. If you did not vote at all, abstained from voting for, or voted versus with regard to the proposals, we kindly question you to vote, or to rethink your vote.
For extra information on the Proposals, please see our Shareholder Vote FAQ.
About iBio, Inc.
iBio is a developer of subsequent-generation biopharmaceuticals and a pioneer in sustainable, plant-based mostly biologics production. Its FastPharming System® combines vertical farming, automated hydroponics, and novel glycosylation technologies to quickly supply superior-good quality monoclonal antibodies, antigens, and other proteins. iBio is creating proprietary biopharmaceuticals for the remedy of cancers, as nicely as fibrotic and infectious health conditions. The Company’s wholly-owned subsidiary, iBio CDMO LLC, presents FastPharming Agreement Improvement and Production Companies alongside with Glycaneering Growth Services™ for state-of-the-art recombinant protein style. For a lot more information and facts, visit www.ibioinc.com.
Make contact with:
Stephen Kilmer iBio, Inc. Investor Relations (646) 274-3580 skilmer@ibioinc.com
Resource: iBio, Inc.
